NCT02815423

Brief Summary

The purpose of the present study is to evaluate the safety and exploratory efficacy of the umbilical cord mesenchymal stem cells for patients with fracture and bone nonunion.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P50-P75 for phase_1

Timeline
Completed

Started Jan 2017

Typical duration for phase_1

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 20, 2016

Completed
2 months until next milestone

First Posted

Study publicly available on registry

June 28, 2016

Completed
6 months until next milestone

Study Start

First participant enrolled

January 1, 2017

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2019

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2020

Completed
Last Updated

June 28, 2016

Status Verified

March 1, 2016

Enrollment Period

2 years

First QC Date

April 20, 2016

Last Update Submit

June 23, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • Radiological progression of bone fusion

    After patients receiving mesenchymal stem cells or placebo, imaging control by X-ray and CT, and then analysis by software(ImageJ ) at 1, 6 and 12 months

    12 months

Secondary Outcomes (3)

  • Comparison of the rate of complications between the 2 groups

    12 months

  • Incidence of increased temperature sensitivity by questionnaire

    6 months

  • Incidence and severity of infections at grafting sites by questionnaire

    6 months

Study Arms (2)

UCMSCs

EXPERIMENTAL

Transplantation of umbilical cord mesenchymal stem cells (UCMSCs) in patients with fracture and bone nonunion.

Biological: UCMSCs

Placebo

PLACEBO COMPARATOR

The patients with fracture and bone nonunion who underwent percutaneous injection of placebo.

Biological: Percutaneous

Interventions

UCMSCsBIOLOGICAL

Transplatation of umbilical cord mesenchymal stem cells

UCMSCs
PercutaneousBIOLOGICAL

Percutaneous injection

Placebo

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Every patient with non union in the site of bone fracture and nonunion.
  • Age more than 18 and less than 60 years old.
  • Nonunion or delayed union.

You may not qualify if:

  • Diagnosis of cancer.
  • Pregnancy or breastfeeding.
  • Patient positive by serology or PCR for HIV, hepatitis B or C infection the patient with Accompanied fracture such as hip fracture that could not weight bearing.
  • Any medical or psychiatric condition that in the researcher´s opinion could affect the patient´s ability to complete the trial or hamper the participation in the trial.
  • Patients do not sign the consent forms

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Fractures, Bone

Interventions

Administration, Cutaneous

Condition Hierarchy (Ancestors)

Wounds and Injuries

Intervention Hierarchy (Ancestors)

Administration, TopicalDrug Administration RoutesDrug TherapyTherapeutics

Central Study Contacts

Xuetao Pei, M.D., Ph.D

CONTACT

Sihan Wang, Ph.D

CONTACT

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 20, 2016

First Posted

June 28, 2016

Study Start

January 1, 2017

Primary Completion

January 1, 2019

Study Completion

January 1, 2020

Last Updated

June 28, 2016

Record last verified: 2016-03

Data Sharing

IPD Sharing
Will share